Axltide

CAS No. 143364-95-8

Axltide( —— )

Catalog No. M30411 CAS No. 143364-95-8

Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).Peptide sequence (KKSRGDYMTMQIG) is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock

Biological Information

  • Product Name
    Axltide
  • Note
    Research use only, not for human use.
  • Brief Description
    Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).Peptide sequence (KKSRGDYMTMQIG) is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).
  • Description
    Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).Peptide sequence (KKSRGDYMTMQIG) is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    143364-95-8
  • Formula Weight
    1514.77
  • Molecular Formula
    C63H107N19O20S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:{Lys}{Lys}{Ser}{Arg}{Gly}{Asp}{Tyr}{Met}{Thr}{Met}{Gln}{Ile}{Gly}

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Wang H, et al. Cellular chromium enhances activation of insulin receptor kinase. Biochemistry. 2005 Jun 7;44(22):8167-75.
molnova catalog
related products
  • Levofloxacin

    Levofloxacin is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections.

  • Ruxolitinib S enanti...

    The chirality of Ruxolitinib (INCB-018424), which is a potent, selective, orally active JAK1/JAK2 inhibitor.

  • S-Ruxolitinib

    Ruxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays.